Melatonin and Zinc Administration on Cardinal Symptoms in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Last updated: July 7, 2022
Sponsor: Laboratorios Viñas, S.A.
Overall Status: Active - Recruiting

Phase

N/A

Condition

Pain (Pediatric)

Fibromyalgia

Chronic Fatigue Syndrome

Treatment

N/A

Clinical Study ID

NCT05454683
IC/LV/MEL-ZN/SFC2
  • Ages 18-65
  • All Genders

Study Summary

The aim of the study is to investigate the effects of oral melatonin and zinc supplementation on core features in individuals with ME/CFS

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Patients between 18 and 65 years of age.
  2. Patients with ME/CFS who met the diagnostic criteria (2011 ICC criteria) from theCentral Sensitization Syndrome Unit (USSC) at the Vall d'Hebron University Hospital.
  3. Patients who freely give written consent.

Exclusion

Exclusion Criteria:

  1. Any active medical condition that explained chronic fatigue (untreated hypothyroidism,sleep apnea, narcolepsy, medication side-effects).
  2. Previous diagnosis not unequivocally resolved (chronic hepatitis, malignancy).
  3. Past or current psychiatric disorders (major depressive disorder with psychotic ormelancholic features, bipolar disorder, schizophrenia, delusional disorder, dementias,anorexia nervosa, bulimia nervosa).
  4. Participation in another clinical trial of the same or different nature in the 30 daysprior to study inclusion.
  5. In the judgment of the investigator, inability to follow the instructions or tocomplete the treatment satisfactorily.
  6. Failure to provide signed informed consent.
  7. Current consumption of medications that may interfere with the results and/or whosewithdrawal may be a relevant problem.
  8. Anticoagulant treatment.
  9. Pregnancy or breast-feeding, or had not used oral contraceptives or other hormonalpreparations in the previous 6 months.
  10. Smoking, alcohol intake or substance abuse.
  11. Severe obesity (class 3 BMI ≥ 40 kg/m2).
  12. Hypersensitivity to melatonin and/or zinc dietary supplements.

Study Design

Total Participants: 106
Study Start date:
September 05, 2022
Estimated Completion Date:
December 31, 2024

Study Description

Myalgic Encephalomyelitis, also known as Chronic Fatigue Syndrome (ME/CFS) is a heterogeneous condition characterized mainly by debilitating and prolonged fatigue, post-exertional malaise (physical, mental and emotional), unrefreshing sleep, cognitive impairment, and orthostatic intolerance with prolonged recovery that is not relieved by rest. Currently, the etiopathogenic mechanisms of ME/CFS are unknown. At present, there is no diagnostic test or effective treatment. MelatoZinc is a food supplement composed of melatonin and zinc, which could contribute to the circadian rhythm homeostasis and regulation of redox imbalance and immune response.

The aim is to evaluate the efficacy and safety of oral treatment with MelatoZinc on the symptomatic complex of fatigue in a larger Spanish ME/CFS population.

This is a single-center, randomized, double-blind, placebo controlled clinical trial. It will include a total of 106 ME/CFS patients who met 2011 ICC criteria for ME/CFS. All patients will take one capsule daily for 16 weeks. Group A will receive MelatoZinc (1 mg melatonin plus 10 mg zinc), and group B will receive a placebo (excipients: isomaltose and magnesium stearate). Clinical symptoms will be evaluated, and standardized questionnaires will be applied to assess the impact of fatigue, pain, anxiety-depression symptoms, sleep quality, dysautonomia, and quality of life. Heart rate variability (HRV) and orthostatic intolerance (10-min NASA Lean Test) will be performed to evaluate autonomic dysfunction. Sleep efficiency will be estimated through an actigraph sensor

Connect with a study center

  • Vall d'Hebron University Hospital

    Barcelona, 08035
    Spain

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.